广谱中和抗体靶向 HIV：进展与挑战。
Broadly neutralizing antibodies targeting HIV: Progress and challenges.
机构信息
The Scintillon Research Institute, 6868 Nancy Drive, San Diego, CA 92121, USA.
The Scintillon Research Institute, 6868 Nancy Drive, San Diego, CA 92121, USA.
出版信息
Clin Immunol. 2023 Dec;257:109809. doi: 10.1016/j.clim.2023.109809. Epub 2023 Oct 16.
Abstract
Anti-HIV broadly neutralizing antibodies (bNAbs) offer a novel approach to treating, preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer of bNAbs have demonstrated that they can control viremia and potentially serve as alternatives or complement antiretroviral therapy (ART). However, antibody decay, persistent latent reservoirs, and resistance impede bNAb treatment. This review discusses recent advancements and obstacles in applying bNAbs and proposes strategies to enhance their therapeutic potential. These strategies include multi-epitope targeting, antibody half-life extension, combining with current and newer antiretrovirals, and sustained antibody secretion.
摘要
抗 HIV 广谱中和抗体 (bNAbs) 为治疗、预防或治愈 HIV 提供了一种新方法。涉及 bNAbs 被动转移的临床前模型和临床试验表明，它们可以控制病毒血症，并可能作为替代或补充抗逆转录病毒治疗 (ART)。然而，抗体衰减、持续潜伏储库和耐药性阻碍了 bNAb 的治疗。本文综述了应用 bNAbs 的最新进展和障碍，并提出了增强其治疗潜力的策略。这些策略包括多表位靶向、抗体半衰期延长、与现有和更新的抗逆转录病毒药物联合使用，以及持续的抗体分泌。
相似文献
1
Broadly neutralizing antibodies targeting HIV: Progress and challenges.广谱中和抗体靶向 HIV：进展与挑战。
Clin Immunol. 2023 Dec;257:109809. doi: 10.1016/j.clim.2023.109809. Epub 2023 Oct 16.
2
The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.广泛中和抗体（bNAbs）在 HIV-1 治疗和预防中的应用。
Viruses. 2024 Jun 4;16(6):911. doi: 10.3390/v16060911.
3
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.广谱中和抗体用于 HIV 预防：全面综述及未来展望。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0015222. doi: 10.1128/cmr.00152-22. Epub 2024 Apr 30.
4
Broadly neutralizing antibodies for the treatment and prevention of HIV infection.广谱中和抗体用于治疗和预防 HIV 感染。
Curr Opin HIV AIDS. 2020 Jan;15(1):49-55. doi: 10.1097/COH.0000000000000600.
5
Use of broadly neutralizing antibodies in pediatric HIV for treatment and remission.广泛中和抗体在儿童HIV治疗与缓解中的应用。
Curr Opin HIV AIDS. 2025 May 1;20(3):279-286. doi: 10.1097/COH.0000000000000927. Epub 2025 Mar 3.
6
Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review.在艾滋病病毒感染者中进行的广泛中和单克隆抗体的临床试验——综述
AIDS Res Ther. 2025 Apr 6;22(1):44. doi: 10.1186/s12981-025-00734-8.
7
Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic.推进 HIV 广谱中和抗体的研发：从发现到临床应用。
Front Public Health. 2021 May 26;9:690017. doi: 10.3389/fpubh.2021.690017. eCollection 2021.
8
Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality.用于人类免疫缺陷病毒治疗的广泛中和抗体：理论上广泛，现实中有限。
Clin Infect Dis. 2023 Mar 21;76(6):1136-1141. doi: 10.1093/cid/ciac835.
9
Broadly neutralizing antibodies for HIV-1 prevention and therapy.广谱中和抗体在 HIV-1 预防和治疗中的应用。
Semin Immunol. 2021 Jan;51:101475. doi: 10.1016/j.smim.2021.101475. Epub 2021 Apr 12.
10
Broadly neutralizing antibodies for HIV treatment and cure approaches.广谱中和抗体在 HIV 治疗和治愈方法中的应用。
Curr Opin HIV AIDS. 2023 Jul 1;18(4):157-163. doi: 10.1097/COH.0000000000000802. Epub 2023 May 4.
引用本文的文献
1
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics.对抗病毒入侵者的纳米级战士：关于纳米抗体作为潜在抗病毒疗法的全面综述
MAbs. 2025 Dec;17(1):2486390. doi: 10.1080/19420862.2025.2486390. Epub 2025 Apr 9.
2
Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?对艾滋病治愈病例的深度思考：我们走过了哪些历程，未来又将如何？
Biomolecules. 2025 Mar 5;15(3):378. doi: 10.3390/biom15030378.
3
Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity.在HIV-1包膜构象可塑性的背景下评估广谱中和抗体（bnAb）的效力。
PLoS Pathog. 2025 Jan 21;21(1):e1012825. doi: 10.1371/journal.ppat.1012825. eCollection 2025 Jan.
4
Unpredicted Protective Function of Fc-Mediated Inhibitory Antibodies for HIV and SARS-CoV-2 Vaccines.Fc介导的HIV和SARS-CoV-2疫苗抑制性抗体的意外保护作用。
J Infect Dis. 2025 Feb 4;231(1):e1-e9. doi: 10.1093/infdis/jiae464.
5
The long road for vaccine development with difficulties and hopes.疫苗研发之路漫长，充满困难与希望。
Emerg Microbes Infect. 2024 Dec;13(1):2396886. doi: 10.1080/22221751.2024.2396886. Epub 2024 Sep 5.
6
The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.广泛中和抗体（bNAbs）在 HIV-1 治疗和预防中的应用。
Viruses. 2024 Jun 4;16(6):911. doi: 10.3390/v16060911.
7
A library-on-library screen reveals the breadth expansion landscape of a broadly neutralizing betacoronavirus antibody.一项文库对文库筛选揭示了一种广泛中和性β冠状病毒抗体的广度扩展情况。
bioRxiv. 2024 Jun 10:2024.06.06.597810. doi: 10.1101/2024.06.06.597810.
8
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.广谱中和抗体用于 HIV 预防：全面综述及未来展望。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0015222. doi: 10.1128/cmr.00152-22. Epub 2024 Apr 30.
9
Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS.在艾滋病毒/艾滋病背景下针对病毒诱导癌症的抗体和基于细胞的疗法。
Pathogens. 2023 Dec 22;13(1):14. doi: 10.3390/pathogens13010014.
10
Rational Design and Characterization of Trispecific Antibodies Targeting the HIV-1 Receptor and Envelope Glycoprotein.靶向HIV-1受体和包膜糖蛋白的三特异性抗体的合理设计与表征
Vaccines (Basel). 2023 Dec 23;12(1):19. doi: 10.3390/vaccines12010019.
本文引用的文献
1
Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study).南非医护人员接种单剂量Ad26.COV2.S疫苗后的血管血栓形成：开放标签、单臂、3B期研究（西松克研究）
BMJ Med. 2023 Mar 23;2(1):e000302. doi: 10.1136/bmjmed-2022-000302. eCollection 2023.
2
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.调整 CAR：修饰嵌合抗原受体 (CAR) T 细胞活性以提高安全性、疗效和灵活性的最新进展。
J Transl Med. 2023 Mar 15;21(1):197. doi: 10.1186/s12967-023-04041-6.
3
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency.双特异性抗体 CAP256.J3LS 以高广度和效力靶向 V2-顶点和 CD4 结合位点。
MAbs. 2023 Jan-Dec;15(1):2165390. doi: 10.1080/19420862.2023.2165390.
4
Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env cells invivo.异体基因编辑的 HIV 特异性 CAR-T 细胞分泌 PD-1 阻断 scFv 增强了体内针对 HIV Env 细胞的特异性细胞毒活性。
Virol Sin. 2023 Apr;38(2):285-295. doi: 10.1016/j.virs.2023.01.003. Epub 2023 Jan 16.
5
Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells.在接受 CD4-MBL CAR/CXCR5 T 细胞治疗的 SIV 感染恒河猴中抗 CAR 抗体的产生。
Front Immunol. 2022 Dec 13;13:1032537. doi: 10.3389/fimmu.2022.1032537. eCollection 2022.
6
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.每 26 周给药一次或与每日口服抗逆转录病毒疗法联合用于 HIV 初始治疗的 Lenacapavir：一项随机、开放标签、阳性对照、2 期临床试验。
Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0.
7
Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1.针对HIV-1的mRNA编码广谱中和抗体组合的合理设计与体内表征
Antibodies (Basel). 2022 Oct 24;11(4):67. doi: 10.3390/antib11040067.
8
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8 T cell immunity.在开始接受抗逆转录病毒疗法时使用广泛中和抗 HIV-1 抗体可维持长期的 CD8 T 细胞免疫。
Nat Commun. 2022 Oct 29;13(1):6473. doi: 10.1038/s41467-022-34171-2.
9
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.抗逆转录病毒治疗起始时使用 3BNC117 和罗米地辛对 HIV-1 感染者进行早期干预：一项 1b/2a 期、随机试验。
Nat Med. 2022 Nov;28(11):2424-2435. doi: 10.1038/s41591-022-02023-7. Epub 2022 Oct 17.
10
HIV-Specific CAR T Cells with CD28 or 4-1BB Signaling Domains Are Phenotypically and Functionally Distinct and Effective at Suppressing HIV and Simian Immunodeficiency Virus.具有 CD28 或 4-1BB 信号结构域的 HIV 特异性 CAR T 细胞在表型和功能上存在差异，并且能够有效抑制 HIV 和猴免疫缺陷病毒。
Immunohorizons. 2022 Oct 11;6(10):693-704. doi: 10.4049/immunohorizons.2200073.
Zotero 插件